Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Canceled)**

2. **(Currently Amended):** A method of treating organ dysfunction caused by ischemia comprising administering an effective amount of G-CSF or fragment thereof to a patient who is subjected to a surgical or interventional procedure in order to obtain a result selected from the group consisting of: to improve organ function, to improve blood flow and ~~and/or~~ to induce revascularization.

3. **(Previously Presented):** The method of claim 2, wherein said pharmaceutical composition or said effective amount of G-CSF or fragment thereof is to be administered before said surgical or interventional procedure.

4. **(Previously Presented):** The method of claim 2, wherein said pharmaceutical composition or said effective amount of G-CSF or fragment thereof is to be administered during said surgical or interventional procedure.

5. **(Previously Presented):** The method of claim 2, wherein said pharmaceutical composition or said effective amount of G-CSF or fragment thereof is to be administered after said surgical or interventional procedure.

6. **(Previously Presented):** The method of claim 5, wherein said pharmaceutical composition or said effective amount of G-CSF or fragment thereof is to be administered between 2 hours and 5 days after said surgical or interventional procedure.

7. **(Previously Presented):** The method of claim 2, wherein said ischemia is selected from the group consisting of myocardial ischemia, cerebral ischemia, renal ischemia, liver ischemia, peripheral muscle tissue ischemia, retinal ischemia and spinal cord ischemia.

8. **(Previously Presented):** The method of claim 7, wherein said myocardial ischemia is caused by hypertension, coronary artery disease (CAD), myocardial infarction, thrombo-embolic events, trauma and/or surgical procedures.

9. **(Previously Presented):** The method of claim 7, wherein said cerebral ischemia is caused by trauma, stroke, thrombo-embolic events, malformation of blood-supplying vessels, multi-infarct disease, cerebral hemorhage, surgical and/or interventional measures.

10. **(Previously Presented):** The method of claim 7, wherein said renal ischemia is caused by thrombo-embolic events, atherosclerosis, malformation of blood-supplying vessels, trauma and/or surgical procedures

11. **(Previously Presented):** The method of claim 7, wherein said liver ischemia is caused by thrombo-embolic events, malformation of blood-supplying vessels, trauma and/or surgical procedures.

12. **(Previously Presented):** The method of claim 7, wherein said peripheral muscle tissue ischemia is caused by thrombo-embolic events, atherosclerosis, malformation of blood-supplying vessels, trauma and/or surgical procedures.

13. **(Previously Presented):** The method of claim 7, wherein said retinal ischemia is caused by thrombo-embolic events, malformation of blood-supplying vessels, trauma and/or surgical procedures.

14. (Previously Presented): The method of claim 7, wherein said spinal cord ischemia is caused by thrombo-embolic events, atherosclerosis, malformation of blood-supplying vessels, trauma and/or surgical procedures.

15. (Previously Presented): The method of claim 2, wherein said ischemia causes organ defects.

16. (Previously Presented): The method of claim 2, wherein said surgical or interventional procedure is a procedure to regain blood flow selected from the group consisting of thrombolysis, ballon angioplasty, stenting, coronary or peripheral bypass surgery and ventriculo-coronary stenting.

17. (Previously Presented): The method of claim 2, wherein said pharmaceutical composition or said effective amount of G-CSF or fragment thereof is capable of recruiting stem and/or progenitor cells.

18. (Previously Presented): The method of claim 17, wherein said stem cells are selected from the group consisting of CD34(+), multipotent adult progenitor cells (MAPC), endothelial progenitor cells (EPC), side population cells (SP) and lineage-negative stem cells.

19. (Previously Presented): The method of claim 18, wherein said multipotent adult progenitor cells are CD34(-), vascular endothelial cadherin(-) and AC133(+) and Flk1(+).

20. (Previously Presented): The method of claim 18, wherein said endothelial progenitor cells are CD34(+), CD31(+) and KDR(+).

21. (Previously Presented): The method of claim 18, wherein said cells of the side population are CD34(-)/ low, c-Kit(+) and Sca-1(+).

22. (Previously Presented): The method of claim 18, wherein said lineage-negative stem cells are CD5(-), CD19(-),CD34(-), c-Kit(+) and Sca-1(+).

23. (Currently Amended): The method of claim 17, wherein said cells are home to organs which harbour defects due to ischemia.

24. (Previously Presented): The method of claim 23, wherein said cells are capable of repairing and/or regenerating said organs.